NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, highlighted the potential of its broad-spectrum antiviral candidate NV-387 in response to the ongoing Bundibugyo Ebola outbreak in the Democratic Republic of Congo and Uganda. The company stated that the oral drug candidate could offer a differentiated approach if proven effective against the virus strain, emphasizing NV-387’s proposed mechanism targeting viral cell attachment pathways common across filoviruses. This positions the candidate as a potential pandemic preparedness tool for Ebola and related viral threats.
NV-387 is a broad-spectrum antiviral drug that the company plans to develop as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections and Measles. The company is currently focused on advancing NV-387 into Phase II human clinical trials. NanoViricides also highlighted its other advanced drug candidate, NV-HHV-1, for the treatment of Shingles.
The company’s platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms for the treatment of various human viral diseases, including HIV/AIDS, Hepatitis B and C, Rabies, Herpes Simplex Virus, Varicella-Zoster Virus, Influenza, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses.
The company noted that its lead drug candidate NV-387 is a nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir, while NV-CoV-2-R is another drug candidate that encapsulates remdesivir. NanoViricides believes that since remdesivir is already US FDA approved, its drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable.
For more information, view the full press release at https://ibn.fm/mm3Z5 and the latest news updates at https://ibn.fm/NNVC.
NanoViricides cautioned that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts, there can be no assurance that any of the company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development, or that successful results in the lab will lead to successful clinical trials or a successful pharmaceutical product.
